Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Gynaecological cancers

4670 - Efficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: Phase III SOLO2 trial (ENGOT Ov-21)


09 Sep 2017


Gynaecological cancers


Cytotoxic Therapy;  Ovarian Cancer


Richard Penson


Annals of Oncology (2017) 28 (suppl_5): v330-v354. 10.1093/annonc/mdx372


R. Penson1, M. Kaminsky-Forrett2, J. Ledermann3, C. Brown4, M. Plante5, J. Korach6, T. Huzarski7, A. Gomez de Liano Lista8, C. Pisano9, M. Friedlander10, N. Colombo11, M. Gropp-Meier12, H. Nakai13, G.S. Sonke14, J. Kim15, I. Vergote16, A. Allen17, E. Pujade-Lauraine18

Author affiliations

  • 1 Medical Gynecologic Oncology, Massachusetts General Hospital, 2114 - Boston/US
  • 2 Medical Oncology, Institut de Cancérologie de Lorraine - Alexis Vautrin, 54519 - Vandoeuvre les Nancy/FR
  • 3 Gynaecological Oncology, UCL Cancer Institute, University College London, WC1E6BT - London/GB
  • 4 Nhmrc Clinical Trials Centre, University of Sydney, Sydney/AU
  • 5 Gynecologic Oncology Division, CHU de Québec-Université Laval, Quebec/CA
  • 6 Gynecologic Oncology Department, Chaim Sheba Medical Center, Tel Hashomer/IL
  • 7 ,, Pomeranian Medical University, Szczecin/PL
  • 8 Servicio De Oncología Médica, Hospital de la Santa Creu i Sant Pau, 8026 - Barcelona/ES
  • 9 Medical Oncology B, Istituto Tumori di Napoli, Naples/IT
  • 10 Medical Oncology, Prince of Wales Hospital, Randwick/AU
  • 11 ,, Istituto Europeo di Oncologia, 20141 - Milan/IT
  • 12 Department Of Gynecology And Obstetrics, Oberschwabenklinik Ravensburg, Ravensburg/DE
  • 13 Department Of Obstetrics And Gynecology, Kindai University, Osaka/JP
  • 14 Medical Oncology, The Netherlands Cancer Institute, 1066CX - Amsterdam/NL
  • 15 College Of Medicine, Obstetrics And Gynecology, Seoul National University, Seoul/KR
  • 16 Gynaecologie-verloskunde, University Hospital Leuven and BGOG, 3000 - Leuven/BE
  • 17 Oncology Global Medicines Development, AstraZeneca, Gaithersburg/US
  • 18 ,, Université Paris Descartes, AP-HP, , - Paris/FR


Abstract 4670


In the Phase III SOLO2 trial (NCT01874353), maintenance treatment with the poly(ADP-ribose) polymerase inhibitor olaparib (Lynparza) was shown to significantly improve progression-free survival (PFS) vs placebo in pts with PSROC and a BRCA1/2 mutation (BRCAm; hazard ratio [HR] 0.30, 95% CI 0.22–0.41; P


SOLO2 enrolled pts who had received ≥2 prior lines of PBC before being in response to their most recent regimen. Pts were randomized 2:1 to receive olaparib tablets (300 mg bid) or placebo. PFS was investigator assessed with modified RECIST v1.1. For the PFS subgroup analyses, subgroups were predefined; HRs were calculated using a Cox proportional hazards model.


Of 295 randomized pts, 195 received olaparib and 99 received placebo. 85 pts in the olaparib arm (43.4%) had received ≥3 prior lines vs 37 pts (37.4%) in the placebo arm.

Table. PFS subgroup analysis by number of prior lines of platinum-based chemotherapy received

Prior lines of platinum-based chemotherapy received

















PFS events, n (%)

57 (51.8)

44 (71.0)

34 (56.7)

19 (95.0)

16 (64.0)

17 (100)

Median PFS, months







Hazard ratio (95% CI)

0.38 (0.26–0.57)

0.24 (0.13–0.42)

0.26 (0.13–0.51)

*Number of prior lines of platinum-based chemotherapy was unknown for one olaparib-arm patient; Progression or death using modified RECIST version 1.1

Pts who had received 2 prior lines of PBC were more likely to have had a platinum-free interval of >12 months (70.9% vs 48.3% and 40.0% for 3 and ≥4 prior lines, respectively in the olaparib arm; 69.4% vs 60.0% and 23.5% placebo) and a complete response at baseline (50.9% vs 36.7% and 48.0% olaparib; 54.8% vs 35.0% and 35.3% placebo) vs pts who had received ≥3 prior lines.


In SOLO2, olaparib maintenance monotherapy improved PFS in pts with PSROC irrespective of the number of prior lines of PBC received.

Clinical trial identification

NCT01874353, 1 June 2017

Legal entity responsible for the study





R. Penson: Honoraria: Amgen, Genentech, AstraZeneca, Endocyte, Eisai, Vascular Biogenics, Baxalta, AbbVie, Clovis, Tesaro; research: Genentech, ImClone, Endocyte, AstraZeneca, Eisai, Amgen, Vascular Biogenics; commercial: Advance Medical. J. Ledermann: Honoraria from AstraZeneca and Pfizer, and consulting fees from AstraZeneca, Clovis Oncology, Pfizer and Roche. M. Friedlander: Research grants and advisory board honoraria from AstraZeneca. N. Colombo: Reports grants and personal fees from AstraZeneca, and personal fees from Roche, Pharmamar, Clovis, Pfizer and Tesaro. M. Gropp-Meier: Honoraria from AstraZeneca. G.S. Sonke: Institutional research funding by AstraZeneca, Merck, Novartis and Roche. A. Allen: Employee of AstraZeneca. E. Pujade-Lauraine: Received advisory board membership and honoraria from AstraZeneca and Pfizer, and advisory board membership, honoraria and speakers\' bureau membership from Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.